What Happened With Viaderma Inc (OTCMKTS:VDRM) At DFCon?

Back towards the end of March, we pointed out that Dr. Christopher Otiko, CEO of development stage biotech company Viaderma Inc (OTCMKTS:VDRM), was set to give a poster presentation at the Diabetic Foot Global Conference (DFCon 2017), at Baylor College of Medicine in Houston, Texas. The event, which took place a few days after we pointed this out, was an opportunity for Otiko to get the word out about Viaderma's lead asset, an antibiotic called Viabecline, and specifically, its impact in a diabetic foot ulcer indication.The situation was this – Otiko has claimed that the drug is more than 96% effective in healing these sorts of ulcers within four weeks. Diabetic foot ulcers are nasty, incredibly painful, prone to infection and – and here's the important part – notoriously difficult to cure and close up once they've opened to wound. If Otiko's claim is accurate, and he was to prove this accuracy at DFCon in front of some of the space's leading minds, Viaderma should run up on its potential to bring in considerable sales revenues and become a standard of care in diabetic wound therapy.Well, the company didn’t run.We don't have access to the presentation (it wasn’t recorded) and so we don't know how it went. There's a photo circulating of what appears to be Otiko and Dr. Armstrong, the guy who founded the event, but that's all we have as far as evidencing the fact that he was there.Fro a peak of around $0.06 a piece just before the event, Viaderma is currently trading at circa $0.03. That's not a great response to what could have been a game changing awareness event.Whatever happened, the company is running up on some seemingly unrelated news. What the release of this news (specifically, it's release without any reference to Viabecline) says about the diabetes ulcer program is unclear. It's drawing speculative volume, however, and that makes it worth us taking a look.Apparently, and according to this press release, Viaderma is getting into the premature ejaculation space. The company has filed with the FDA to get a premature ejaculation drug approved as an over the counter asset. There's not too much in the way of information that we can glean from the release, but it looks as though the company is trying to get a spray on treatment approved that will serve as an alternative to the orally ingested therapies that dominate the market right now – Viagra and Cialis. There are already spray versions of this sort of thing available in the US, both available OTC and by prescription, so the entry of Viaderma into this space is basically the equivalent of a generic entry in the drug/pharma space.Just because it's entering a generic space, however, doesn’t mean there's no potential. This is a $1.3 billion market (premature ejaculation), of which topical administration assets (sprays, creams etc.) account for more than $700 million.From a timeframe perspective, Viaderma expects the FDA to turn the application around within an eight-week period. We think this is pretty optimistic, but if it proves accurate, this could be an on-shelf asset before the end of the second quarter.So what's the importance of this? Well, it's a revenue stream, and a relatively simple one at that. If the company can get this branded and start picking up some sales, it's going to provide some sentiment support, and that's very much needed right now in the wake of the recent decline. We're not expecting massive numbers, but a solid stream of a few percentage points of the available market could make a considerable difference for a company that's valued at just a few million dollars right now.Bottom line is this: we're going to follow this premature ejaculation story pretty closely to see how it plays into the bigger picture, but our primary focus for Viaderma is the diabetic foot ulcer target. That's where the big money is near term, and that's what we want to see the company push out information about.We will be updating our subscribers as soon as we know more. For the latest updates on VDRM, sign up below!Disclosure: We have no position in VDRM and have not been compensated for this article.